[Newsmp] In the first half, the Ministry of Food and Drug Safety approved a slightly lower number of clinical trials compared to the corresponding period in the previous year.
According to the MFDS information platform (https://nedrug.mfds.go.kr/), 225 companies obtained approvals for 556 clinical trial plans. This shows a decrease of 17 trials from the same timeframe in the previous year, during which 573 trials secured the green light.
In terms of institutions, IQVIA Korea took the lead with 19 approvals during this period, followed by Chong Kun Dang Pharmaceutical with 16 approvals, and Novotech Asia Korea with 15 approvals.
ASAN Foundation Asan Medical Center and PPD recorded 12 approvals, Boryung Pharmaceutical had 11, and both Daewoong Pharmaceutical and Parexel Korea achieved 10 approvals, making a total of 8 companies with double-digit figures.
Additionally, GSK, Roche Korea, and Janssen Korea received 9 approvals each, with Seoul National University Hospital and Novartis Korea attaining 8 approvals, and AstraZeneca Korea and Huons obtaining 7 approvals each.
Gilead Sciences Korea, DongKoo Bio & Pharma, ICON Clinical Research Korea, and Pharmaceutical Research Associates Korea secured 6 approvals each.
Furthermore, Medpace, Dongkwang Pharm, Mother's Pharmaceutical, Myungmoon Pharmaceutical, Bayer Korea, Samsung Medical Center, INC Research South Korea, Aprogen Pharmaceuticals, Severance Hospital, Worldwide Clinical Trials Korea, BMS Korea, AbbVie Korea, and Korea Pharma were authorized for 5 clinical trial plans each.
